“OmniActive remains steadfast in delivering innovative, effective and safe ingredients to the marketplace,” said Lynda M. Doyle, Sr. VP of Global Marketing, OmniActive. “CurcuWIN is a truly differentiated ingredient in the increasingly crowded enhanced curcumin market because our robust clinical program is showing how its higher bioavailability correlates to greater efficacy at a lower dose – what we’ve termed ‘bioavailability with a purpose.’ And now, by gaining GRAS self-affirmation, CurcuWIN sets itself apart yet again.”
In a human clinical trial comparing commercial curcumin products, CurcuWIN increased relative absorption of total curcuminoids 46 times over standard curcumin. Moreover, in the recent, ground-breaking FloMeD (Flow Mediated Dilation and Curcumin), CurcuWIN was shown to help support healthy blood flow and circulation at a low dose.
Produced using OmniActive’s proprietary UltraSOL technology, CurcuWIN is a turmeric extract with 20% curcuminoids with a similar profile to that found naturally in turmeric. CurcuWIN is manufactured under cGMP at OmniActive's ISO certified and FDA audited manufacturing facility in Pune, India. CurcuWIN is supported by a strong clinical and safety program including in vitro, in vivo and multiple human clinical trials.